Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Journal: The Lancet. Oncology
Published: March 03, 2017
U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 22, 2013
Showing 1-2 of 2
Last Updated: 09/26/2026